The effects of chemotherapeutic agents on differentiated chordoma cells

Bayrak O. F., Aydemir E., Gulluoglu S., Sahin F., Sevli S., Yalvac M. E., ...More

JOURNAL OF NEUROSURGERY-SPINE, vol.15, no.6, pp.620-624, 2011 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 6
  • Publication Date: 2011
  • Doi Number: 10.3171/2011.7.spine10798
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.620-624
  • Keywords: chordoma, all-trans retinoic acid, chemotherapeutic agent, differentiation therapy, oncology, TRANS-RETINOIC ACID, POTENTIAL THERAPEUTIC TARGETS, SKULL BASE CHORDOMAS, CANCER CELLS, APOPTOSIS, GROWTH, ADENOCARCINOMA, CISPLATIN, PATHWAYS, KINASES
  • Kocaeli University Affiliated: No


Object. Chordoma is a rare type of malignant bone tumor and is known to arise from the remnants of the notochord. Resistance to chemotherapy makes the treatment of chordoma difficult; therefore, new approaches need to be developed to cure this disease. Differentiation therapy, using various differentiating agents, is attracting oncologists as a common therapeutic method to treat other tumors. Based on forcing cells to mature into other lineages, differentiation therapy might be an available method to treat chordomas in addition to conventional therapies.